Protagenic Therapeutics, Inc. (PTIX)
NASDAQ: PTIX · IEX Real-Time Price · USD
0.765
-0.175 (-18.62%)
At close: Jul 2, 2024, 4:00 PM
0.803
+0.038 (4.99%)
After-hours: Jul 2, 2024, 4:38 PM EDT
Company Description
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders.
Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses.
Protagenic Therapeutics, Inc. is headquartered in New York, New York.
Protagenic Therapeutics, Inc.
Country | United States |
Founded | 1994 |
IPO Date | Jan 5, 2016 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 1 |
CEO | Dr. Garo H. Armen Ph.D. |
Contact Details
Address: 149 Fifth Avenue, Suite 500 New York, New York 10010 United States | |
Phone | (212) 994-8200 |
Website | protagenic.com |
Stock Details
Ticker Symbol | PTIX |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001022899 |
CUSIP Number | 74365N103 |
ISIN Number | US74365N2027 |
Employer ID | 06-1390025 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Garo H. Armen Ph.D. | Co-Founder and Executive Chairman of the Board |
Dr. Alexander Kenneth Arrow C.F.A., M.D. | Chief Financial Officer and Secretary |
Dr. Andrew Slee Ph.D. | Chief Operating Officer |
Dr. Robert Benjamin Stein M.D., Ph.D. | Chief Medical Officer and Director |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jun 14, 2024 | S-3 | Registration statement under Securities Act of 1933 |
May 24, 2024 | 8-K | Current Report |
May 22, 2024 | 8-K | Current Report |
May 15, 2024 | 10-Q | Quarterly Report |
May 14, 2024 | 10-K/A | [Amend] Annual report |
Apr 24, 2024 | 10-K/A | [Amend] Annual report |
Apr 1, 2024 | 10-K | Annual Report |
Mar 21, 2024 | 8-K | Current Report |
Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Dec 15, 2023 | 8-K | Current Report |